214 related articles for article (PubMed ID: 9458985)
1. In vitro activity of cefepime and ceftazidime against 197 nosocomial blood stream isolates of streptococci: a multicenter sample.
Pfaller MA; Marshall SA; Jones RN
Diagn Microbiol Infect Dis; 1997 Dec; 29(4):273-6. PubMed ID: 9458985
[TBL] [Abstract][Full Text] [Related]
2. Nosocomial streptococcal blood stream infections in the SCOPE Program: species occurrence and antimicrobial resistance. The SCOPE Hospital Study Group.
Pfaller MA; Jones RN; Marshall SA; Edmond MB; Wenzel RP
Diagn Microbiol Infect Dis; 1997 Dec; 29(4):259-63. PubMed ID: 9458983
[TBL] [Abstract][Full Text] [Related]
3. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
4. Comparative activity and spectrum of broad-spectrum beta-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North America: 2001-2002).
Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2003 Oct; 47(2):435-40. PubMed ID: 14522519
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of selected cephalosporins and erythromycin against staphylococci and pneumococci isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998.
Jones RN; Jenkins SG; Hoban DJ; Pfaller MA; Ramphal R
Diagn Microbiol Infect Dis; 2000 Jun; 37(2):93-8. PubMed ID: 10863103
[TBL] [Abstract][Full Text] [Related]
6. In vitro evaluation of contemporary beta-lactam drugs tested against viridans group and beta-haemolytic streptococci.
Pfaller MA; Jones RN
Diagn Microbiol Infect Dis; 1997 Apr; 27(4):151-4. PubMed ID: 9154412
[TBL] [Abstract][Full Text] [Related]
7. Antibiotic susceptibility of streptococci isolated from blood from neutropenic patients.
Piérard D; de Meyer A; Lauwers S
Pathol Biol (Paris); 1994 May; 42(5):471-4. PubMed ID: 7824316
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro activity of cefepime against strains isolated from intensive care and haematology patients.
Vanpoucke H; Claeys G; De Grauwe E; Verschraegen G
Acta Clin Belg; 2000; 55(1):16-21. PubMed ID: 10783503
[TBL] [Abstract][Full Text] [Related]
9. Cefepime: a review of its use in the management of hospitalized patients with pneumonia.
Chapman TM; Perry CM
Am J Respir Med; 2003; 2(1):75-107. PubMed ID: 14720024
[TBL] [Abstract][Full Text] [Related]
10. Inducible amp C beta-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE).
Pfaller MA; Jones RN; Marshall SA; Coffman SL; Hollis RJ; Edmond MB; Wenzel RP
Diagn Microbiol Infect Dis; 1997 Aug; 28(4):211-9. PubMed ID: 9327251
[TBL] [Abstract][Full Text] [Related]
11. Clinical applications of a new parenteral antibiotic in the treatment of severe bacterial infections.
Holloway WJ; Palmer D
Am J Med; 1996 Jun; 100(6A):52S-59S. PubMed ID: 8678098
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial susceptibility of viridans group streptococci.
Tuohy M; Washington JA
Diagn Microbiol Infect Dis; 1997 Dec; 29(4):277-80. PubMed ID: 9458986
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of cefepime against multidrug-resistant Gram-negative bacilli, viridans group streptococci and Streptococcus pneumoniae from a cross-Canada surveillance study.
Low DE; de Azavedo J; ; Davidson R
Can J Infect Dis; 1999 Mar; 10(2):122-7. PubMed ID: 22346377
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial activity of FK-037, a new broad-spectrum cephalosporin. International in vitro comparison with cefepime and ceftazidime.
Frei R; Jones RN; Pignatari AC; Yamane N; Marco F; Hoban DJ
Diagn Microbiol Infect Dis; 1994 Mar; 18(3):167-73. PubMed ID: 7924209
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of cefepime and other broad-spectrum beta-lactams tested against 129 mec A-negative Staphylococcus spp. isolates: a multicenter sample.
Marshall SA; Wilke WW; Chen YS; Pfaller MA; Jones RN
Diagn Microbiol Infect Dis; 1998 Jan; 30(1):65-9. PubMed ID: 9488834
[TBL] [Abstract][Full Text] [Related]
16. In vitro inferiority of ceftazidime compared with other beta-lactams for viridans group Streptococcus bacteremia in pediatric oncology patients: implications for antibiotic choices.
Paulus S; Dobson S; Rassekh S; Blondel-Hill E
J Pediatr Hematol Oncol; 2009 Apr; 31(4):267-9. PubMed ID: 19346878
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group.
Jones RN; Pfaller MA; Doern GV; Erwin ME; Hollis RJ
Diagn Microbiol Infect Dis; 1998 Mar; 30(3):215-28. PubMed ID: 9572029
[TBL] [Abstract][Full Text] [Related]
19. Activity of cefepime against nosocomial blood culture isolates.
Qadri SM; Cunha BA; Ueno Y; Abumustafa F; Imambaccus H; Tullo DD; Domenico P
J Antimicrob Chemother; 1995 Sep; 36(3):531-6. PubMed ID: 8830018
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial susceptibility of major pathogens of orofacial odontogenic infections to 11 beta-lactam antibiotics.
Kuriyama T; Karasawa T; Nakagawa K; Nakamura S; Yamamoto E
Oral Microbiol Immunol; 2002 Oct; 17(5):285-9. PubMed ID: 12354209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
